PharmaShots Connects Brands & Decision-Makers with Custom Media Solutions PharmaShots Provides Curated News & Insights for the Biopharma & Healthcare Industry PharmaShots is Empowering Decision Makers with Actionable Insights Amplify Your Brand with PharmaShots’ Expert Content Creation & Marketing Solutions PharmaShots Enables Brands to Strategically Connect with Their Target Audiences Deliver Your News to the Right Audience with PharmaShots Newswire CXO TALKS CXO TALKSCXO Talks Podcast | The Road to Acquisition: Oncolytics’ CEO Jared Kelly on Clinical Data, IP & Pharma Partnerships CXO TALKSPharmaShots CXO Talks | Women’s History Month Special: A Conversation with Dr. Emanuela Offidani of Tris Pharma CXO TALKSPharmaShots CXO Talks | A Conversation with Liz Benditt, Founder & CEO, The Balm Box CXO TALKSCXO Talks: Vikas Sharma Reveals QurAlis’ Bold Vision for the Future of Neuroscience EXCLUSIVE INTERVIEW EXCLUSIVEExclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight EXCLUSIVEExclusive: Dr. Mónica Domínguez from Smile Train in a Stimulating Conversation with PharmaShots on Why a Healthy Mouth is a Happy Mind EXCLUSIVEExclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots EXCLUSIVEExclusive Coverage: Dr. Ikshit Sharma from AIMIL Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEAdvancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots EXCLUSIVEDecoding Approval: Moitreyee Chatterjee-Kishore from Astellas in an Exclusive Conversation with PharmaShots EXCLUSIVEAdvancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots EXCLUSIVEExclusive: David Esposito in an Illuminating Discussion with PharmaShots LATEST NEWSStay up-to-date Merck and Gilead Report FDA Approval of Trodelvy + Keytruda for Previously Untreated PD-L1+ TNBC 5 hours ago Merck KGaA to Acquire Bio-Techne for ~$11.3B 6 hours ago Ionis Inks ex-US Deal with Recordati for Zilganersen in Alexander Disease 7 hours ago Otsuka Reports P-IIIb Trial Data on Centanafadine in ADHD and Comorbid Anxiety 9 hours ago Pfizer’s Ibrance Combination Receives FDA Approval as a Maintenance Therapy for HR+, HER2+ Metastatic Breast Cancer 10 hours ago Antares Therapeutics Inks ~$1.9B Deal with Novartis for Undruggable Oncology Targets 11 hours ago Read More Your Daily Dose of Biopharma News & Insights Delivered to Your Inbox. Join the PharmaShots Family of 20000+ subscribers Subscribe Now
Merck and Gilead Report FDA Approval of Trodelvy + Keytruda for Previously Untreated PD-L1+ TNBC 5 hours ago
Pfizer’s Ibrance Combination Receives FDA Approval as a Maintenance Therapy for HR+, HER2+ Metastatic Breast Cancer 10 hours ago
